Impact of timing of RUTF dose reduction and visit frequency on acute malnutrition treatment effectiveness in Mali: A 2x2 Factorial Cluster-Randomized Controlled Trial

Technical Summary: Impact of RUTF Dose Reduction Timing and Visit Frequency on Acute Malnutrition Treatment in Mali

Problem Statement
Severe acute malnutrition (SAM) in children under five is typically treated in outpatient settings using Ready-to-Use Therapeutic Food (RUTF). Recent updates to global guidelines (2023) suggest reducing the RUTF dose once a child with SAM transitions to the moderate acute malnutrition (MAM) stage. However, evidence regarding the optimal timing of this dose reduction (immediate vs. a transition period) and the ideal frequency of follow-up visits during the MAM phase (weekly vs. fortnightly) remains unclear. Current protocols vary, with some reducing doses immediately upon reaching MAM criteria and others maintaining higher doses for a transition period, while visit frequencies often shift from weekly to fortnightly as children improve. The lack of evidence on these specific operational parameters creates uncertainty in optimizing treatment effectiveness, cost-efficiency, and child survival.

Methodology
The study was a prospective, 2x2 factorial cluster-randomized controlled non-inferiority trial conducted in the Nara health district of Mali between April and December 2023.

• Design: The study randomized 39 health areas (clusters) into four arms to test two independent factors:
  1. Timing of RUTF Dose Reduction: Immediate reduction upon reaching MAM criteria (MUAC ≥115mm) versus a 2-week transition period (requiring 3 consecutive visits with MUAC ≥115mm) before reducing the dose.
  2. Visit Frequency in MAM Phase: Weekly visits versus fortnightly (every two weeks) visits once the child enters the MAM phase.
• Intervention Protocol: All children received a simplified, combined treatment protocol. Children admitted with SAM (MUAC <115mm or edema) received 2 daily RUTF sachets, while those with MAM (MUAC 115–124mm) received 1 daily sachet. Recovery was defined as MUAC ≥125mm and absence of edema for two consecutive visits.
• Population: A total of 6,249 children with MUAC <125mm or edema were admitted, including 1,451 children with SAM.
• Analysis: The primary outcome was recovery. The study employed linear and logistic mixed models with health areas and treatment sites as random effects. Non-inferiority was assessed with a 10% margin. Analyses were conducted using both Intention-to-Treat (ITT) and Per-Protocol (PP) approaches.

Key Results

• Recovery Rates: Both interventions demonstrated non-inferiority regarding recovery rates compared to the standard protocols.
  • Visit Frequency: Fortnightly visits in the MAM phase resulted in non-inferior recovery rates compared to weekly visits (98% recovery in both groups).
  • Dose Reduction Timing: Immediate dose reduction upon reaching MAM criteria resulted in non-inferior recovery rates compared to the 2-week transition period (93% vs. 95% for SAM admissions).
• Secondary Outcomes:
  • Duration of Treatment: Fortnightly visits significantly increased the duration of treatment by approximately 2.5 weeks (median 8 weeks vs. 4 weeks for MAM admissions) compared to weekly visits.
  • Resource Consumption: The increased duration associated with fortnightly visits led to a significantly higher consumption of RUTF (an average of 23–26 additional sachets per child).
  • Weight Gain Velocity: Children with fortnightly visits showed lower weight gain velocity. Similarly, immediate dose reduction resulted in a lower weight gain velocity compared to the 2-week transition, though this difference was not statistically significant after adjustment.
  • Regression Risk: There was a non-significant trend toward a higher proportion of children regressing from MAM back to SAM in the immediate transition group (3.17% difference in adjusted analysis) compared to the 2-week transition group.
  • Adherence: No significant differences were observed in defaulting rates or missed visits between the weekly and fortnightly groups.

Significance and Claims
The authors claim that while immediate dose reduction and fortnightly visits do not compromise the primary outcome of recovery, they introduce trade-offs in treatment efficiency and resource utilization.

• Visit Frequency: The study concludes that while fortnightly visits are non-inferior for recovery, they extend treatment duration and increase RUTF consumption by nearly 50% per child. Consequently, the authors recommend maintaining weekly visits throughout treatment where feasible to ensure shorter treatment duration and lower resource use.
• Dose Reduction Timing: Although immediate dose reduction is non-inferior for recovery, the observed trend toward increased regression to SAM and slightly lower weight gain velocities suggests potential risks. The authors recommend including a 2-week transition period before reducing the RUTF dose for children admitted with SAM to ensure steady progress and minimize the risk of relapse.

The paper positions these findings as the first evidence testing these specific operational variables in a factorial design, providing actionable guidance for national programs to balance treatment effectiveness with resource constraints. The authors emphasize that their recommendations are based on the specific context of accessible treatment sites (short distances to care) and may require adaptation in settings with significant access barriers.